On 2 Dec 2023, the updated results of these two studies with extended follow-up were presented in 2023 ESMO_ASIA.

Plexium has begun dosing in a Phase 1 trial for its oral drug PLX-4545, a molecular glue degrader targeting the previously "undruggable" transcription factor IKZF2, also known as Helios.

The search for more sensitive and safer specific RET inhibitors to provide precision treatment and personalized treatment for cancer patients will be the main research direction in the future.

The European Commission has sanctioned Blueprint Medicines' drug AYVAKYT® (avapritinib) as the exclusive therapeutic option for indolent systemic mastocytosis.

On 3 Dec 2023, the latest clinical result of MCLA-129, an anti-EGFR/c-MET bispecific antibody, for the treatment on non-small cell lung cancer was reported in 2023 ESMO_ASIA.

Clover Biopharmaceuticals, Ltd. has announced the enrollment of the first group of participants for its Phase I clinical trial evaluating the SCB-1019 vaccine against Respiratory Syncytial Virus (RSV).

The primary reporter is the first person who provides individual safety information, regardless of whether the reporter is a medical professional.

The FDA is reviewing the updated New Drug Application (NDA) for TransCon PTH (also known as Palopegteriparatide) meant for the treatment of hypoparathyroidism in adults.

Protease inhibitors are drugs that inhibit proteases, enzymes crucial in various biological processes.

Vertex Pharmaceuticals Incorporated declared favorable outcomes from its Phase 2 trial assessing various dosages of the targeted NaV1.8 inhibitor, VX-548, in individuals suffering from painful diabetic peripheral neuropathy.

If the applicant / marketing authorisation holder has submitted an RMP for the product, the RMP submitted later should adopt an updated format.

Wugen Unveils Initial Results from Early-Stage Clinical Assessment of WU-CART-007 in Hard-to-Combat Hematologic Malignancies at the Yearly American Hematology Conference.